Clinical trials: Teratogens
Neural Tube Defects, Congenital Abnormalities
Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens.
- Conditions
- Neural Tube Defects, Congenital Abnormalities, Teratogens
- Trial name
- NCT05883761
- Where
- 5 sites in Eswatini
- Volunteers
- 50,075 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation